Drivers of Successful Reimbursement Decisions of Orphan Drugs in Spain
Omakase has presented the last POSTER "Drivers of Successful Reimbursement Decis [...]
Omakase has participated in a expert panel on “EU Joint HTA of Orphan Drugs and the Likely Local Implications” organised by World Orphan Drug Congress Europe in Sitges
Omakase has participated in a expert panel on "EU Joint HTA of Orphan Drugs and [...]
Analysis of the negative reimbursement of Orphan Drugs in the Spanish National Health System (2019-2022)
Omakase presented a POSTER "Analysis of the negative reimbursement of Orphan Dru [...]
Do you want to know factors influencing Orphan PnR in Spain?
Omakase has presented at ISPOR 2022 in Vienna the following POSTER: "Do you want [...]
Efficiency of Third-generation antiseizure medications in Spain for Drug-resistant epilepsy: A Cost-per-Number Needed to Treat Analysis
Omakase presented the POSTER "Efficiency of Third-generation antiseizure medicat [...]
“Value Contribution of Olipudase Alfa therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA)”
At ISPOR Europe 2022, Omakase presented the POSTER "Value Contribution of Olipud [...]
Omakase Consulting keeps growing with a new area of Institutional Relationships and Communication
Omakase Consulting, in line with its strategy and thrive for continuous growth a [...]
Studio the economically justifiable price in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy
We are very pleased to share a new publication of which OMAKASE is a co-author t [...]
MCDA methodology in the Farmacia Hospitalaria journal
Today, we are pleased to share with you the publication of our latest work using [...]
Alicia Gil, CEO Omakase Consulting attended a session held in the Spanish National Congress organised by FEDER (Spanish Rare Diseases Organisation)
Alicia Gil, CEO Omakase Consulting attended yesterday a session held in the Span [...]